Compare RMBI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMBI | TNXP |
|---|---|---|
| Founded | 1887 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.0M | 199.7M |
| IPO Year | 2019 | 2008 |
| Metric | RMBI | TNXP |
|---|---|---|
| Price | $15.94 | $13.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.7K | ★ 486.9K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | 27.17 | ★ 91.75 |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | $31.18 | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $12.77 | $9.40 |
| 52 Week High | $16.59 | $29.19 |
| Indicator | RMBI | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 58.19 |
| Support Level | $15.75 | $13.32 |
| Resistance Level | $16.17 | $14.85 |
| Average True Range (ATR) | 0.25 | 0.71 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 45.69 | 55.73 |
Richmond Mutual Bancorp Inc is a bank holding company. Along with its subsidiary, it is mainly engaged in attracting deposits from the general public, as well as brokered deposits, and investing those funds in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one- to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. It also obtains funds by utilizing Federal Home Loan Bank (FHLB) advances. These funds are generally invested in investment securities, including mortgage-backed and mortgage-related securities and agency and municipal bonds. The Group's primary market area includes Wayne and Shelby counties in Indiana and Shelby, Miami, and Franklin counties in Ohio.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.